随着癌症治疗领域的不断进步，嵌合抗原受体T细胞疗法（CAR-T细胞疗法）已成为血液恶性肿瘤治疗的革命性技术。自2017年8月全球首个CAR-T细胞产品Kymriah获得美国FDA批准上市以来，这一疗法在短短数年间取得了有目共睹的进展。该产品最初被用于 ...

Novartis' CAR-T Kymriah has become the first therapy in the category to be approved for the treatment of relapsed/refractory follicular lymphoma, ahead of Gilead Sciences' rival Yescarta.

Novartis' CAR-T therapy Kymriah racked up back-to-back approvals in acute lymphoblastic leukaemia and large B-cell lymphoma a few years ago, but hasn't added to its label since. Now, a bid to move ...

Previously, it was available only as part of a clinical research trial. The CAR-T therapy, called Kymriah, costs £282,000 per patient, but the NHS has negotiated a undisclosed lower price with ...

Wild Wild Riches Megaways dema Novartis establishes first Asian CAR-T production facility to fill Kymriah production gap! The mechanism f ...